Desonide

Identification

Summary

Desonide is a topical corticosteroid used for the symptomatic treatment of inflammatory and pruritic manifestations of corticosteroid responsive dermatoses.

Brand Names

Desonate, Desowen, Desrx, Lokara, Tridesilon, Verdeso

Generic Name

Desonide

DrugBank Accession Number

DB01260

Background

A nonfluorinated corticosteroid anti-inflammatory agent used topically for dermatoses.

Type

Small Molecule

Groups

Approved, Investigational

Structure

Similar Structures

Weight: Average: 416.5073
Monoisotopic: 416.219888756
Chemical Formula: C₂₄H₃₂O₆

Synonyms

11β,21-dihydroxy-16α,17-[(1-methylethylidene)bis(oxy)]pregna-1,4-diene-3,20-dione
11β,21-dihydroxy-16α,17-isopropylidenedioxypregna-1,4-diene-3,20-dione
11β,21-dihydroxy-16α,17α-isopropylidenedioxypregna-1,4-diene-3,20-dione
16α-hydroxyprednisole-16,17-acetonide
16α-hydroxyprednisolone-16α,17-acetonide
16α,17α-isopropylidenedioxyprednisolone
Desfluorotriamcinolone acetonide
Desonida
Desonide
Desonidum

External IDs

D-2083
D2083

Pharmacology

Indication

For the relief of the inflammatory and pruritic manifestations of corticosteroid responsive dermatose.

Reduce drug development failure rates

Build, train, & validate machine-learning models
with evidence-based and structured datasets.

See how

Build, train, & validate predictive machine-learning models with structured datasets.

See how

Associated Conditions

Contraindications & Blackbox Warnings

Prevent Adverse Drug Events Today

Tap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.

Learn more

Avoid life-threatening adverse drug events with our Clinical API

Learn more

Pharmacodynamics

Desonide is a synthetic nonfluorinated corticosteroid for topical dermatologic use. The corticosteroids constitute a class of primarily synthetic steroids used topically as anti-inflammatory and antipruritic agents.

Mechanism of action

Like other topical corticosteroids, desonide has anti-inflammatory, antipruritic and vasoconstrictive properties. The drug binds to cytosolic glucocorticoid receptors. This complex migrates to the nucleus and binds to genetic elements on the DNA. This activates and represses various genes. However corticosteroids are thought to act by the induction of phospholipase A2 inhibitory proteins, collectively called lipocortins. It is postulated that these proteins control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes by inhibiting the release of their common precursor arachidonic acid. Arachidonic acid is released from membrane phospholipids by phospholipase A2.

Target	Actions	Organism
AGlucocorticoid receptor	agonist	Humans

Absorption

Topical corticosteroids can be absorbed from normal intact skin, inflammation and/or other disease processes in the skin may increase percutaneous absorption.

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism

Not Available

Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects

Improve decision support & research outcomes

With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!

See the data

Improve decision support & research outcomes with our structured adverse effects data.

See a data sample

Toxicity

Not Available

Pathways

Not Available

Pharmacogenomic Effects/ADRs

Not Available

Interactions

Drug Interactions

This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.

Drug	Interaction
Integrate drug-drug interactions in your software
Abametapir	The serum concentration of Desonide can be increased when it is combined with Abametapir.
Acarbose	The risk or severity of hyperglycemia can be increased when Desonide is combined with Acarbose.
Acetohexamide	The risk or severity of hyperglycemia can be increased when Desonide is combined with Acetohexamide.
Acetyldigitoxin	The risk or severity of adverse effects can be increased when Desonide is combined with Acetyldigitoxin.
Albiglutide	The risk or severity of hyperglycemia can be increased when Desonide is combined with Albiglutide.
Allogeneic processed thymus tissue	The therapeutic efficacy of Allogeneic processed thymus tissue can be decreased when used in combination with Desonide.
Alogliptin	The risk or severity of hyperglycemia can be increased when Desonide is combined with Alogliptin.
Aminoglutethimide	The therapeutic efficacy of Desonide can be decreased when used in combination with Aminoglutethimide.
Anthrax vaccine	The therapeutic efficacy of Anthrax vaccine can be decreased when used in combination with Desonide.
Apalutamide	The serum concentration of Desonide can be decreased when it is combined with Apalutamide.

Identify potential medication risks

Easily compare up to 40 drugs with our drug interaction checker.

Get severity rating, description, and management advice.

Learn more

Food Interactions

No interactions found.

Products

Drug product information from 10+ global regions

Our datasets provide approved product information including:
dosage, form, labeller, route of administration, and marketing period.

Access now

Access drug product information from over 10 global regions.

Access now

International/Other Brands

Desocort (Galderma) / Tridesilon (Bayer)

Brand Name Prescription Products

Name	Dosage	Strength	Route	Labeller	Marketing Start	Marketing End
Desocort Cream 0.05%	Cream	.05 %	Topical	Galderma	1994-12-31	2007-08-02
Desocort Lotion - 0.05%	Lotion	.05 %	Topical	Galderma	1994-12-31	2016-08-04
Desocort Ointment - 0.05%	Ointment	.05 %	Topical	Galderma	1994-12-31	2016-08-04
Desonate	Gel	0.5 mg/1g	Topical	SkinMedica	2007-03-30	Not applicable
Desonate	Gel	0.5 mg/1g	Topical	LEO Pharma Inc.	2018-10-01	Not applicable
Desonate	Gel	0.5 mg/1g	Topical	Bayer HealthCare Pharmaceuticals Inc.	2006-10-20	Not applicable
Desonate	Gel	0.5 mg/1g	Topical	Intendis Inc.	2010-01-28	Not applicable
Desonide	Cream	0.5 mg/1g	Topical	Rebel Distributors	2006-04-11	Not applicable
Desonide	Cream	0.5 mg/1g	Topical	Physicians Total Care, Inc.	2006-04-11	Not applicable
Desonide	Cream	0.5 mg/1g	Topical	Padagis Israel Pharmaceuticals Ltd	2006-04-11	2023-08-31

Generic Prescription Products

Name	Dosage	Strength	Route	Labeller	Marketing Start	Marketing End
Desonide	Ointment	0.5 mg/1g	Topical	Teligent Pharma, Inc.	2019-03-13	Not applicable
Desonide	Cream	0.5 mg/1g	Topical	Alembic Pharmaceuticals, Inc.	2022-12-08	Not applicable
Desonide	Lotion	0.5 mg/1g	Topical	Physicians Total Care, Inc.	2004-05-17	Not applicable
Desonide	Cream	0.5 mg/1g	Topical	Cosette Pharmaceuticals, Inc.	2016-08-19	Not applicable
Desonide	Lotion	0.5 mg/1mL	Topical	E. Fougera & Co. a division of Fougera Pharmaceuticals Inc.	2002-03-19	Not applicable
Desonide	Ointment	0.5 mg/1g	Topical	Taro Pharmaceuticals U.S.A., Inc.	1994-08-03	Not applicable
Desonide	Lotion	0.5 mg/1mL	Topical	Actavis Pharma, Inc.	2009-05-28	Not applicable
Desonide	Cream	0.5 mg/1g	Topical	bryant ranch prepack	2020-06-17	Not applicable
Desonide	Cream	0.5 mg/1g	Topical	Proficient Rx LP	2013-08-01	Not applicable
Desonide	Cream	0.5 mg/1g	Topical	Rebel Distributors	1992-06-30	Not applicable

Mixture Products

Name	Ingredients	Dosage	Route	Labeller	Marketing Start	Marketing End
PRECORT-A KREM	Desonide (0.125 %) + Clioquinol (3 %)	Cream	Topical	KOÇAK FARMA İLAÇ VE KİMYA SAN. A.Ş.	2020-08-14	Not applicable
PRECORT-A POMAD	Desonide (0.125 %) + Clioquinol (3 %)	Ointment	Topical	KOÇAK FARMA İLAÇ VE KİMYA SAN. A.Ş.	2020-08-14	Not applicable
PREDNOL-A 30 GR KREM	Desonide (0.125 %) + Clioquinol (3 %)	Cream	Topical	GENSENTA İLAÇ SANAYİ VE TİCARET A.Ş.	2020-08-14	Not applicable
PREDNOL-A 30 GR POMAD	Desonide (0.125 %) + Clioquinol (3 %)	Ointment	Topical	GENSENTA İLAÇ SANAYİ VE TİCARET A.Ş.	2020-08-14	Not applicable

Chemical Identifiers

UNII: J280872D1O
CAS number: 638-94-8
InChI Key: WBGKWQHBNHJJPZ-LECWWXJVSA-N
InChI: InChI=1S/C24H32O6/c1-21(2)29-19-10-16-15-6-5-13-9-14(26)7-8-22(13,3)20(15)17(27)11-23(16,4)24(19,30-21)18(28)12-25/h7-9,15-17,19-20,25,27H,5-6,10-12H2,1-4H3/t15-,16-,17-,19+,20+,22-,23-,24+/m0/s1
IUPAC Name: (1S,2S,4R,8S,9S,11S,12S,13R)-11-hydroxy-8-(2-hydroxyacetyl)-6,6,9,13-tetramethyl-5,7-dioxapentacyclo[10.8.0.0^{2,9}.0^{4,8}.0^{13,18}]icosa-14,17-dien-16-one
SMILES: [H][C@@]12C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)C=C[C@]12C

References

Synthesis Reference

Bernstein, S. and Allen, G.R., Jr.; U.S. Patent 2,990,401; June 27, 1961; assigned to American Cyanamid Company. Diassi, P.A. and Principe, P.A.; U.S.Patent 3,549,498; December 22, 1970; assigned to E.R. Squibb & Sons, inc.

General References

Not Available

External Links

Human Metabolome Database: HMDB0015389
KEGG Drug: D03696
PubChem Compound: 5311066
PubChem Substance: 46506186
ChemSpider: 4470603
RxNav: 3254
ChEBI: 204734
ChEMBL: CHEMBL1201109
ZINC: ZINC000004212851
Therapeutic Targets Database: DAP001188
PharmGKB: PA164776996
RxList: RxList Drug Page
Drugs.com: Drugs.com Drug Page
PDRhealth: PDRhealth Drug Page
Wikipedia: Desonide

MSDS

Download (73.7 KB)

Clinical Trials

Clinical Trials

Phase	Status	Purpose	Conditions	Count
4	Completed	Treatment	Atopic Dermatitis	3
4	Completed	Treatment	Hyperpigmentation	1
4	Withdrawn	Treatment	Psoriasis	1
3	Completed	Treatment	Atopic Dermatitis	2
3	Unknown Status	Treatment	Atopic Dermatitis	1
1	Completed	Treatment	Vasoconstriction	1
1	Recruiting	Basic Science	Healthy Subjects (HS)	1

Pharmacoeconomics

Manufacturers

Not Available

Packagers

Actavis Group
Ameri-Pac Inc.
Contract Pharm
Dispensing Solutions
Diversified Healthcare Services Inc.
DPT Laboratories Ltd.
E. Fougera and Co.
Galderma Laboratories
Intendis Inc.
Ivax Pharmaceuticals
Major Pharmaceuticals
Medisca Inc.
Nycomed Inc.
Palmetto Pharmaceuticals Inc.
Perrigo Co.
Pharmedix
Physicians Total Care Inc.
Stiefel Labs
Taro Pharmaceuticals USA

Dosage Forms

Form	Route	Strength
Cream	Topical
Cream	Cutaneous	0.050 g
Cream	Topical	0.1 g
Emulsion	Topical	0.05 g
Cream	Cutaneous	0.0005 g
Emulsion	Topical	0.050 mg
Cream	Topical	100 mg
Lotion	Topical	.05 %
Cream	Topical	0.05 %
Ointment
Solution	Topical
Cream
Gel	Topical	0.5 mg/1g
Cream	Topical	0.05 g
Lotion	Topical	0.1 g
Cream	Topical	3 g
Cream	Topical	.5 mg/1g
Lotion	Topical	.5 mg/1g
Lotion	Topical	0.5 mg/1g
Ointment	Topical	0.5 mg/1g
Ointment	Topical	0.5 mg/01g
Solution	Topical
Cream	Topical	0.5 mg/1g
Emulsion	Cutaneous	0.0500 g
Lotion	Topical	0.05 %
Ointment	Topical	0.05 %
Lotion	Topical
Lotion	Topical	0.5 mg/1mL
Cream	Topical
Cream	Topical	0.05 % w/w
Ointment	Topical	0.05 % w/w
Ointment	Topical	0.125 %
Cream	Topical	0125 %
Ointment	Topical
Ointment	Ophthalmic	0.25 %
Ointment	Ophthalmic	5 G
Solution / drops	Ophthalmic	0.25 %
Solution / drops	Ophthalmic	10 ml
Lotion	Topical
Cream	Topical	0.05 G/100G
Ointment		0.05 G/100G
Solution	Topical	0.05 G/100G
Cream	Topical	.05 %
Ointment	Topical	.05 %
Cream	Topical	0.03 g/60g
Cream	Topical	.5 mg / g
Ointment	Topical	.5 mg / g
Aerosol, foam	Topical	0.05 %
Aerosol, foam	Topical	0.5 mg/1g

Prices

Unit description	Cost	Unit
DesOwen Lot w/Cetaphil Cream 0.05% Kit Box	255.84USD	box
Desowen 0.05% ointment kit	217.2USD	kit
Desowen 0.05% cream kit	212.4USD	kit
DesOwen 0.05% Lotion 118ml Bottle	183.17USD	bottle
Desonide powder	152.39USD	g
DesOwen 0.05% Lotion 59ml Bottle	123.38USD	bottle
Desonide 0.05% Lotion 118ml Bottle	76.75USD	bottle
Desonide 0.05% Lotion 59ml Bottle	50.86USD	bottle
Desonide 0.05% Ointment 60 gm Tube	41.76USD	tube
Desonide 0.05% Cream 60 gm Tube	41.48USD	tube
Desonide 0.05% Ointment 15 gm Tube	16.09USD	tube
Desonide 0.05% Cream 15 gm Tube	16.07USD	tube
Desowen 0.05% cream	2.43USD	g
Desonide 0.05% cream	0.81USD	g
Desocort 0.05 % Ointment	0.32USD	g
Pms-Desonide 0.05 % Cream	0.28USD	g
Pms-Desonide 0.05 % Ointment	0.28USD	g
Desocort 0.05 % Lotion	0.16USD	g

DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.

Patents

Patent Number	Pediatric Extension	Approved	Expires (estimated)
US8460641	No	2013-06-11	2028-11-05
US8962000	No	2015-02-24	2025-08-31
US6730288	No	2004-05-04	2019-09-08
US7029659	No	2006-04-18	2019-09-08
US6387383	No	2002-05-14	2020-08-03
US9492384	No	2016-11-15	2025-08-31

Properties

State

Solid

Experimental Properties

Property	Value	Source
melting point (°C)	257-260	Bernstein, S. and Allen, G.R., Jr.; U.S. Patent 2,990,401; June 27, 1961; assigned to American Cyanamid Company. Diassi, P.A. and Principe, P.A.; U.S.Patent 3,549,498; December 22, 1970; assigned to E.R. Squibb & Sons, inc.
water solubility	Practically insoluble	Not Available
logP	1.4	Not Available

Predicted Properties

Property	Value	Source
Water Solubility	0.0594 mg/mL	ALOGPS
logP	2.31	ALOGPS
logP	1.9	Chemaxon
logS	-3.8	ALOGPS
pKa (Strongest Acidic)	13.75	Chemaxon
pKa (Strongest Basic)	-2.9	Chemaxon
Physiological Charge	0	Chemaxon
Hydrogen Acceptor Count	6	Chemaxon
Hydrogen Donor Count	2	Chemaxon
Polar Surface Area	93.06 Å²	Chemaxon
Rotatable Bond Count	2	Chemaxon
Refractivity	112.06 m³·mol^-1	Chemaxon
Polarizability	44.59 Å³	Chemaxon
Number of Rings	5	Chemaxon
Bioavailability	1	Chemaxon
Rule of Five	Yes	Chemaxon
Ghose Filter	Yes	Chemaxon
Veber's Rule	No	Chemaxon
MDDR-like Rule	No	Chemaxon

Predicted ADMET Features

Property	Value	Probability
Human Intestinal Absorption	+	0.9764
Blood Brain Barrier	+	0.9382
Caco-2 permeable	-	0.6162
P-glycoprotein substrate	Substrate	0.7998
P-glycoprotein inhibitor I	Non-inhibitor	0.5837
P-glycoprotein inhibitor II	Inhibitor	0.6045
Renal organic cation transporter	Non-inhibitor	0.7573
CYP450 2C9 substrate	Non-substrate	0.8268
CYP450 2D6 substrate	Non-substrate	0.9078
CYP450 3A4 substrate	Substrate	0.7545
CYP450 1A2 substrate	Non-inhibitor	0.909
CYP450 2C9 inhibitor	Non-inhibitor	0.8729
CYP450 2D6 inhibitor	Non-inhibitor	0.9544
CYP450 2C19 inhibitor	Non-inhibitor	0.9521
CYP450 3A4 inhibitor	Non-inhibitor	0.536
CYP450 inhibitory promiscuity	Low CYP Inhibitory Promiscuity	0.9129
Ames test	Non AMES toxic	0.8938
Carcinogenicity	Non-carcinogens	0.949
Biodegradation	Not ready biodegradable	0.9766
Rat acute toxicity	2.5316 LD50, mol/kg	Not applicable
hERG inhibition (predictor I)	Weak inhibitor	0.9573
hERG inhibition (predictor II)	Non-inhibitor	0.67

ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)

Not Available

Spectra

Spectrum	Spectrum Type	Splash Key
Predicted GC-MS Spectrum - GC-MS	Predicted GC-MS	Not Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)	Predicted LC-MS/MS	Not Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)	Predicted LC-MS/MS	Not Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)	Predicted LC-MS/MS	Not Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)	Predicted LC-MS/MS	Not Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)	Predicted LC-MS/MS	Not Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)	Predicted LC-MS/MS	Not Available

Targets

Build, predict & validate machine-learning models

Use our structured and evidence-based datasets to unlock new
insights and accelerate drug research.

Learn more

Use our structured and evidence-based datasets to unlock new insights and accelerate drug research.

Learn more

Details1. Glucocorticoid receptor

Kind: Protein
Organism: Humans
Pharmacological action: Yes
Actions: Agonist

General Function: Zinc ion binding
Specific Function: Receptor for glucocorticoids (GC). Has a dual mode of action: as a transcription factor that binds to glucocorticoid response elements (GRE), both for nuclear and mitochondrial DNA, and as a modula...
Gene Name: NR3C1
Uniprot ID: P04150
Uniprot Name: Glucocorticoid receptor
Molecular Weight: 85658.57 Da

References

Russell GM, Henley DE, Leendertz J, Douthwaite JA, Wood SA, Stevens A, Woltersdorf WW, Peeters BW, Ruigt GS, White A, Veldhuis JD, Lightman SL: Rapid glucocorticoid receptor-mediated inhibition of hypothalamic-pituitary-adrenal ultradian activity in healthy males. J Neurosci. 2010 Apr 28;30(17):6106-15. doi: 10.1523/JNEUROSCI.5332-09.2010. [Article]
Shaw JR, Gabor K, Hand E, Lankowski A, Durant L, Thibodeau R, Stanton CR, Barnaby R, Coutermarsh B, Karlson KH, Sato JD, Hamilton JW, Stanton BA: Role of glucocorticoid receptor in acclimation of killifish (Fundulus heteroclitus) to seawater and effects of arsenic. Am J Physiol Regul Integr Comp Physiol. 2007 Feb;292(2):R1052-60. Epub 2006 Oct 12. [Article]
Otte C, Wust S, Zhao S, Pawlikowska L, Kwok PY, Whooley MA: Glucocorticoid receptor gene, low-grade inflammation, and heart failure: the Heart and Soul study. J Clin Endocrinol Metab. 2010 Jun;95(6):2885-91. doi: 10.1210/jc.2009-2251. Epub 2010 Apr 6. [Article]

Enzymes

Details1. Cytochrome P450 3A4

Kind: Protein
Organism: Humans
Pharmacological action: No
Actions: Substrate
Inducer

General Function: Vitamin d3 25-hydroxylase activity
Specific Function: Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation react...
Gene Name: CYP3A4
Uniprot ID: P08684
Uniprot Name: Cytochrome P450 3A4
Molecular Weight: 57342.67 Da

References

Rendic S: Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448. [Article]
Verdeso monograph [File]

Drug created at May 16, 2007 17:31 / Updated at December 06, 2023 02:33

Desonide

Identification

Structure for Desonide (DB01260)

Pharmacology

Interactions

Products

Categories

Chemical Identifiers

References

Clinical Trials

Pharmacoeconomics

Properties

Spectra

Targets

References

Enzymes

References